3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
venetoclax
136
Cytarabine
106
Cyclophosphamide
104
Specimen Handling
94
fludarabine
86
Azacitidine
84
Biopsy
71
Rituximab
45
Methotrexate
42
Daunorubicin
41
fludarabine phosphate
40
Vincristine
35
Magnetic Resonance Spectroscopy
35
Dexamethasone
35
blinatumomab
31
Injections
31
Decitabine
31
Granulocyte Colony-Stimulating Factor
29
Mycophenolic Acid
28
Whole-Body Irradiation
27
Idarubicin
27
ibrutinib
26
Tacrolimus
26
Prednisone
26
Etoposide
26
Busulfan
25
Melphalan
24
Doxorubicin
24
acalabrutinib
23
Calcium Dobesilate
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Inosine Monophosphate
×
Other hematologic neoplasm
×
90 days
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled